Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

NCT04707768 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

456

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia Associated With Chronic Kidney Disease (CKD)

Interventions

DRUG: Vadadustat
DRUG: Mircera®

Sponsor

Akebia Therapeutics